Nearly 7 million Americans are living with Alzheimer’s Disease, and millions more may be undiagnosed in the unimpaired or early impaired stages. As we enter an era of earlier detection and diagnosis, a new opportunity is emerging–one that allows individuals and families to engage sooner in care, planning, and support.  

At a moment when longevity, wellness, and proactive health are reshaping how Americans think about aging, scientifically grounded and clinically validated advances are redefining Alzheimer’s disease care. This shift is especially evident in diagnostics, where newly FDA-cleared blood tests are transforming the landscape. These tools are more scalable, more affordable, and less invasive than current diagnostic standards and can be used alongside clinical assessment to help identify the disease earlier for both patients and providers.  

California has more Alzheimer's patients than any other state, with an estimated 720,000 residents affected — including over 24,000 in Sacramento County alone. Alzheimer's was the third leading cause of death among Californians in 2015, and with 22% of the state's population projected to be over 65 by 2040, the urgency to invest in long-term care solutions is growing. In response, Governor Newsom launched a Master Plan for Aging in 2019, with initiatives focused on dementia-capable adult day services and early detection through primary care.